Microcap Allurion Technologies (NYSE:ALUR) surged ~31% in after-hours trading Thursday after posting preliminary data on weight loss associated with its gastric balloon in combination with Novo ...
Shares of Allurion Technologies on Friday surged a day after the company said it received positive results about the effectiveness of its gastric balloon in combination with a low dose of the ...
Roth MKM keeps a Buy rating and $16 price target on Allurion Technologies (ALUR) after its initial results from Allurion Program-GLP-1 combo.
Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced its intention to initiate a clinical study on the combination ...
Reports Q4 revenue $5.6M, compared to $8.2M for the same period in 2023. The year-over-year decrease in revenue was primarily due to the ...
Allurion Technologies, Inc. develops treatments for obesity. The Allurion Program is a weight loss platform that combines the Allurion Gastric Balloon, a swallowable, procedure-less gastric ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback